EU/3/00/016: Orphan designation for the treatment of acute respiratory distress syndrome (ARDS)


Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in February 2009 on request of the sponsor.

On 17 January 2001, orphan designation (EU/3/00/016) was granted by the European Commission to Byk Gulden Lomberg Chemische Fabrick GmbH, Germany, for lusupultide for the treatment of acute respiratory distress syndrome.

The sponsor Gulden Lomberg Chemische Fabrik GmbH changed name to ALTANA Pharma AG in September 2002.

The sponsorship was transferred to Nycomed GmbH, Germany in October 2007.

Key facts

Active substance
Intended use
Treatment of acute respiratory distress syndrome (ARDS)
Orphan designation status
EU designation number
Date of designation
Nycomed GmbH
Byk-Gulden-Str. 2
D-78467 Konstanz
Tel. +49 7531 840
Fax +49 7531 842474

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating